SG11201408617PA - Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders - Google Patents
Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disordersInfo
- Publication number
- SG11201408617PA SG11201408617PA SG11201408617PA SG11201408617PA SG11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA
- Authority
- SG
- Singapore
- Prior art keywords
- alkyl
- international
- con
- treatment
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664936P | 2012-06-27 | 2012-06-27 | |
| EP12174669 | 2012-07-02 | ||
| PCT/EP2013/063537 WO2014001464A1 (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408617PA true SG11201408617PA (en) | 2015-01-29 |
Family
ID=49782305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408617PA SG11201408617PA (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9580438B2 (zh) |
| EP (1) | EP2867237A1 (zh) |
| JP (2) | JP6272846B2 (zh) |
| KR (1) | KR102155559B1 (zh) |
| CN (1) | CN104540831B (zh) |
| AU (2) | AU2013283318B2 (zh) |
| BR (1) | BR112014032581A8 (zh) |
| CA (1) | CA2877589C (zh) |
| EA (1) | EA029718B1 (zh) |
| HK (1) | HK1204474A1 (zh) |
| IL (1) | IL236463A0 (zh) |
| IN (1) | IN2014MN02562A (zh) |
| MX (1) | MX350418B (zh) |
| MY (1) | MY167785A (zh) |
| NZ (1) | NZ702618A (zh) |
| SG (1) | SG11201408617PA (zh) |
| UA (1) | UA116541C2 (zh) |
| WO (1) | WO2014001464A1 (zh) |
| ZA (1) | ZA201409194B (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013283318B2 (en) * | 2012-06-27 | 2017-11-23 | 4Sc Ag | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders |
| PT3119762T (pt) | 2014-03-20 | 2021-08-31 | Capella Therapeutics Inc | Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro |
| AU2015231215B2 (en) | 2014-03-20 | 2019-07-18 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
| US10112939B2 (en) | 2014-08-21 | 2018-10-30 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| WO2017013210A1 (en) * | 2015-07-21 | 2017-01-26 | 4Sc Ag | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds |
| WO2017053537A1 (en) | 2015-09-23 | 2017-03-30 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
| KR102527784B1 (ko) | 2016-04-07 | 2023-04-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조정제로서 유용한 헤테로시클릭 아미드 |
| CA3078267A1 (en) | 2017-10-27 | 2019-05-02 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 |
| US20220033418A1 (en) | 2018-09-13 | 2022-02-03 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| CN109020990A (zh) * | 2018-09-20 | 2018-12-18 | 广西壮族自治区药用植物园 | 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途 |
| KR102119150B1 (ko) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| US20230301950A1 (en) | 2020-06-26 | 2023-09-28 | Raqualia Pharma Inc. | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
| CN116942819A (zh) * | 2023-04-24 | 2023-10-27 | 珠海市人民医院 | 微管相关丝氨酸/苏氨酸样激酶抑制剂在制备治疗肿瘤的药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167569A (en) | 1976-12-09 | 1979-09-11 | Imperial Chemical Industries Limited | Pyrimido[1,2-a ]benzimidazole derivatives |
| CA2458533C (en) | 2001-10-09 | 2011-01-04 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JO2724B1 (en) | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| US7541367B2 (en) | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| CN101448506A (zh) | 2005-12-02 | 2009-06-03 | 拜尔健康护理有限责任公司 | 通过抑制有丝分裂酶激酶治疗癌症的吡咯并三嗪衍生物 |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| EP2947073B1 (en) * | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| AU2013283318B2 (en) * | 2012-06-27 | 2017-11-23 | 4Sc Ag | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders |
-
2013
- 2013-06-27 AU AU2013283318A patent/AU2013283318B2/en not_active Ceased
- 2013-06-27 EA EA201500050A patent/EA029718B1/ru not_active IP Right Cessation
- 2013-06-27 IN IN2562MUN2014 patent/IN2014MN02562A/en unknown
- 2013-06-27 BR BR112014032581A patent/BR112014032581A8/pt not_active Application Discontinuation
- 2013-06-27 UA UAA201500560A patent/UA116541C2/uk unknown
- 2013-06-27 KR KR1020157001782A patent/KR102155559B1/ko active IP Right Grant
- 2013-06-27 SG SG11201408617PA patent/SG11201408617PA/en unknown
- 2013-06-27 CA CA2877589A patent/CA2877589C/en not_active Expired - Fee Related
- 2013-06-27 MY MYPI2014003556A patent/MY167785A/en unknown
- 2013-06-27 US US14/411,795 patent/US9580438B2/en active Active
- 2013-06-27 CN CN201380034461.4A patent/CN104540831B/zh not_active Expired - Fee Related
- 2013-06-27 JP JP2015519098A patent/JP6272846B2/ja not_active Expired - Fee Related
- 2013-06-27 EP EP13731822.6A patent/EP2867237A1/en not_active Withdrawn
- 2013-06-27 MX MX2014015938A patent/MX350418B/es active IP Right Grant
- 2013-06-27 NZ NZ702618A patent/NZ702618A/en not_active IP Right Cessation
- 2013-06-27 WO PCT/EP2013/063537 patent/WO2014001464A1/en active Application Filing
-
2014
- 2014-12-12 ZA ZA2014/09194A patent/ZA201409194B/en unknown
- 2014-12-25 IL IL236463A patent/IL236463A0/en unknown
-
2015
- 2015-05-26 HK HK15105006.4A patent/HK1204474A1/zh unknown
-
2017
- 2017-02-27 US US15/443,180 patent/US20170240556A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000285A patent/JP2018076360A/ja active Pending
- 2018-02-22 AU AU2018201275A patent/AU2018201275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9580438B2 (en) | 2017-02-28 |
| KR102155559B1 (ko) | 2020-09-15 |
| WO2014001464A1 (en) | 2014-01-03 |
| AU2018201275A1 (en) | 2018-03-15 |
| NZ702618A (en) | 2016-12-23 |
| IN2014MN02562A (zh) | 2015-07-24 |
| BR112014032581A2 (pt) | 2017-06-27 |
| IL236463A0 (en) | 2015-02-26 |
| CN104540831B (zh) | 2017-11-07 |
| MX2014015938A (es) | 2015-07-21 |
| BR112014032581A8 (pt) | 2018-08-14 |
| AU2013283318A1 (en) | 2015-01-22 |
| JP2018076360A (ja) | 2018-05-17 |
| ZA201409194B (en) | 2017-08-30 |
| AU2013283318B2 (en) | 2017-11-23 |
| CA2877589C (en) | 2019-11-26 |
| US20150158878A1 (en) | 2015-06-11 |
| JP6272846B2 (ja) | 2018-01-31 |
| EP2867237A1 (en) | 2015-05-06 |
| EA029718B1 (ru) | 2018-05-31 |
| UA116541C2 (uk) | 2018-04-10 |
| US20170240556A1 (en) | 2017-08-24 |
| JP2015525742A (ja) | 2015-09-07 |
| HK1204474A1 (zh) | 2015-11-20 |
| EA201500050A1 (ru) | 2015-09-30 |
| CN104540831A (zh) | 2015-04-22 |
| CA2877589A1 (en) | 2014-01-03 |
| KR20150037877A (ko) | 2015-04-08 |
| MX350418B (es) | 2017-09-06 |
| MY167785A (en) | 2018-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201407837WA (en) | Beta-hairpin peptidomimetics | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201908729UA (en) | Phenyl derivatives as pge2 receptor modulators | |
| SG11201402986RA (en) | Kinase inhibitors | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
| SG11201901817SA (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201809674QA (en) | Adenine derivatives as protein kinase inhibitors | |
| SG11201908235RA (en) | An isoxazole derivatives as nuclear receptor agonists and used thereof | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201805142RA (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |